Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.

Pinilla-Ibarz J, Sweet KL, Corrales-Yepez GM, Komrokji RS.

Onco Targets Ther. 2016 Aug 10;9:4937-57. doi: 10.2147/OTT.S102504. Review.

2.

Expression, purification and biological activity assessment of romiplostim biosimilar peptibody.

Fayaz S, Fard-Esfahani P, Golkar M, Allahyari M, Sadeghi S.

Daru. 2016 Jul 11;24(1):18. doi: 10.1186/s40199-016-0156-7.

3.

Hyaluronan Depolymerization by Megakaryocyte Hyaluronidase-2 Is Required for Thrombopoiesis.

Petrey AC, Obery DR, Kessler SP, Flamion B, de la Motte CA.

Am J Pathol. 2016 Sep;186(9):2390-403. doi: 10.1016/j.ajpath.2016.05.004.

PMID:
27398974
4.

Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm.

Yang Y, Akada H, Nath D, Hutchison RE, Mohi G.

Blood. 2016 Jun 30;127(26):3410-23. doi: 10.1182/blood-2015-11-679431.

PMID:
27081096
5.

A Potential Mechanism of High-Dose Ticagrelor in Modulating Platelet Activity and Atherosclerosis Mediated by Thymic Stromal Lymphopoietin Receptor.

Mao Y, Peng Y, Zeng Q, Cheng L, Wang B, Mao X, Meng K, Liu Y, Lian Y, Li D.

PLoS One. 2015 Oct 30;10(10):e0141464. doi: 10.1371/journal.pone.0141464.

6.

Regulating billions of blood platelets: glycans and beyond.

Grozovsky R, Giannini S, Falet H, Hoffmeister KM.

Blood. 2015 Oct 15;126(16):1877-84. doi: 10.1182/blood-2015-01-569129. Review.

7.

Inhibition of Thrombopoietin/Mpl Signaling in Adult Hematopoiesis Identifies New Candidates for Hematopoietic Stem Cell Maintenance.

Kohlscheen S, Wintterle S, Schwarzer A, Kamp C, Brugman MH, Breuer DC, Büsche G, Baum C, Modlich U.

PLoS One. 2015 Jul 6;10(7):e0131866. doi: 10.1371/journal.pone.0131866.

8.

Recombinant human thrombopoietin treatment promotes hematopoiesis recovery in patients with severe aplastic anemia receiving immunosuppressive therapy.

Wang H, Dong Q, Fu R, Qu W, Ruan E, Wang G, Liu H, Wu Y, Song J, Xing L, Guan J, Li L, Shao Z.

Biomed Res Int. 2015;2015:597293. doi: 10.1155/2015/597293.

9.

New frontiers for platelet CD154.

Dewitte A, Tanga A, Villeneuve J, Lepreux S, Ouattara A, Desmoulière A, Combe C, Ripoche J.

Exp Hematol Oncol. 2015 Mar 1;4:6. doi: 10.1186/s40164-015-0001-6.

PMID:
25763299
Free PMC Article
10.

Efficient generation of megakaryocytes from human induced pluripotent stem cells using food and drug administration-approved pharmacological reagents.

Liu Y, Wang Y, Gao Y, Forbes JA, Qayyum R, Becker L, Cheng L, Wang ZZ.

Stem Cells Transl Med. 2015 Apr;4(4):309-19. doi: 10.5966/sctm.2014-0183.

11.

The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling.

Grozovsky R, Begonja AJ, Liu K, Visner G, Hartwig JH, Falet H, Hoffmeister KM.

Nat Med. 2015 Jan;21(1):47-54. doi: 10.1038/nm.3770.

12.

Integrated differential transcriptome maps of Acute Megakaryoblastic Leukemia (AMKL) in children with or without Down Syndrome (DS).

Pelleri MC, Piovesan A, Caracausi M, Berardi AC, Vitale L, Strippoli P.

BMC Med Genomics. 2014 Dec 5;7:63. doi: 10.1186/s12920-014-0063-z.

13.

Ott1 (Rbm15) regulates thrombopoietin response in hematopoietic stem cells through alternative splicing of c-Mpl.

Xiao N, Laha S, Das SP, Morlock K, Jesneck JL, Raffel GD.

Blood. 2015 Feb 5;125(6):941-8. doi: 10.1182/blood-2014-08-593392.

14.

Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice.

Bender M, Giannini S, Grozovsky R, Jönsson T, Christensen H, Pluthero FG, Ko A, Mullally A, Kahr WH, Hoffmeister KM, Falet H.

Blood. 2015 Feb 5;125(6):1014-24. doi: 10.1182/blood-2014-07-587857.

15.

Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide.

Baird JH, Minniti CP, Lee JM, Tian X, Wu C, Jackson M, Alam S, Taylor JG 6th, Kato GJ.

Br J Haematol. 2015 Mar;168(5):737-46. doi: 10.1111/bjh.13203.

16.

JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation.

Besancenot R, Roos-Weil D, Tonetti C, Abdelouahab H, Lacout C, Pasquier F, Willekens C, Rameau P, Lecluse Y, Micol JB, Constantinescu SN, Vainchenker W, Solary E, Giraudier S.

Blood. 2014 Sep 25;124(13):2104-15. doi: 10.1182/blood-2014-03-559815.

17.

Mpl traffics to the cell surface through conventional and unconventional routes.

Cleyrat C, Darehshouri A, Steinkamp MP, Vilaine M, Boassa D, Ellisman MH, Hermouet S, Wilson BS.

Traffic. 2014 Sep;15(9):961-82. doi: 10.1111/tra.12185.

18.

Serum Thrombopoietin and cMpl Expression in Thrombocytopenia of Different Etiologies.

Vianello F, Vettore S, Tezza F, Toni LD, Scandellari R, Sambado L, Treleani M, Fabris F.

Hematol Rep. 2014 Mar 26;6(1):4996. doi: 10.4081/hr.2014.4996.

19.

Primary thrombocytosis in children.

Kucine N, Chastain KM, Mahler MB, Bussel JB.

Haematologica. 2014 Apr;99(4):620-8. doi: 10.3324/haematol.2013.092684. Review.

20.

Erythropoiesis from human embryonic stem cells through erythropoietin-independent AKT signaling.

Kim WS, Zhu Y, Deng Q, Chin CJ, He CB, Grieco AJ, Dravid GG, Parekh C, Hollis RP, Lane TF, Bouhassira EE, Kohn DB, Crooks GM.

Stem Cells. 2014 Jun;32(6):1503-14. doi: 10.1002/stem.1677.

Items per page

Supplemental Content

Support Center